Volpi A, Cavalli A, Franzosi M G, Maggioni A, Mauri F, Santoro E, Tognoni G
Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico (GISSI) Coordinating Center, Milan, Italy.
Am J Cardiol. 1989 May 15;63(17):1174-8. doi: 10.1016/0002-9149(89)90174-4.
The 1-year prognosis of 293 patients discharged alive from the hospital after acute myocardial infarction (AMI), who experienced primary ventricular fibrillation (VF) in the acute phase, was compared with that of a reference group of 6,337 patients identified from the same population included in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto miocardico (GISSI) trial. There was no difference in the 6- and 12-month mortality between the patients with primary VF and the reference group (3.7 vs 2.7% and 4.1 vs 4.2%, respectively). Survival of the 2 groups was also similar when patients were stratified according to infarct site (anterior and posterior), and whether or not they received treatment with streptokinase during AMI. Thus, long-term mortality of patients discharged alive after AMI complicated by primary VF is low and is not influenced by previous fibrinolytic therapy or by infarct site. The excess mortality of patients with primary VF is confined to the hospital phase, after which survivors represent a low-risk subgroup.
对293例急性心肌梗死（AMI）后存活出院且在急性期发生原发性心室颤动（VF）的患者的1年预后，与从意大利心肌梗死链激酶研究组（GISSI）试验纳入的同一人群中确定的6337例患者的参照组进行了比较。原发性VF患者与参照组在6个月和12个月死亡率方面无差异（分别为3.7%对2.7%和4.1%对4.2%）。当根据梗死部位（前壁和后壁）以及他们在AMI期间是否接受链激酶治疗对患者进行分层时，两组的生存率也相似。因此，AMI并发原发性VF后存活出院患者的长期死亡率较低，且不受既往溶栓治疗或梗死部位的影响。原发性VF患者的额外死亡率局限于住院阶段，在此之后幸存者属于低风险亚组。
